Approach to discriminate subgroups in multiple sclerosis with cerebrospinal fluid (CSF) basic inflammation indices and TNF-α, IL-1β, IL-6, IL-8

Brain Research Bulletin

Volumn 61, Issue 3, 2003, Pages 327-346

  Kleine, Tilmann O ^a   Zwerenz, Peter ^b   Graser, Claus ^c   Zöfel, Peter ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b DPC Biermann GmbH   (Germany)

^c Computing Centre of the University ^*  (Germany)

Author keywords

Clinically definite MS; Clinically probable MS; Long disease course MS; Multiple sclerosis (MS); Primary progressive MS; Relapsing remitting MS

Indexed keywords

IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ASTROCYTE; BLOOD BRAIN BARRIER; CELL COUNT; CELL TRANSFER; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISABILITY; DISEASE COURSE; FEMALE; HUMAN; IMMUNOGLOBULIN PRODUCTION; INFLAMMATION; LYMPHOCYTE; MACROPHAGE; MALE; MICROGLIA; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

EID: 0041589148     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(03)00096-0     Document Type: Conference Paper

References (92)

1. Adams C.W.M., Poston R.N., Buk S.J., Sidhu Y.S., Vipond H. Inflammatory vasculitis in multiple sclerosis. J. Neurol. Sci. 69:1985;269-283.
2. Bitsch A., da Costa C., Bunkowski S., Weber F., Rieckmann P., Brück W. Identification of macrophage populations expressing tumor necrosis factor-α in acute multiple sclerosis. Acta Neuropathol. 95:1998;373-377.
3. Bitsch A., Schuchardt J., Bunkowski S., Kuhlmann T., Brück W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain. 123:2000;1174-1183.
4. Brosnan C.F., Cannella B., Battistini L., Raine C.S. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology. 45:1995;S16-S21.
5. Brosnan C.F., Raine C.S. Mechanisms of immune injury in multiple sclerosis. Brain Pathol. 6:1996;243-257.
6. Browning D.D., Diehl W.C., Hsu M.H., Schraufstatter I.U., Ye R.D. Autocrine regulation of interleukin-8 production in human monocytes. Am. J. Physiol. Cell Mol. Physiol. 279:2000;L1129-L1136.
7. Brück W., Porada P., Poser S., Rieckmann P., Hanefeld F., Kretzschmar H.A., Lassmann H. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann. Neurol. 38:1995;788-796.
8. Cannon J.G., Tompkins R.G., Gelfand J.A., Michie H.R., Standford G.G., van der Meer J.W.M., Endres S., Lonnemann G., Corsetti J., Chernow B., Wilmore D.W., Wolff S.M., Burke J.F., Dinarello C.A. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J. Infect. Dis. 161:1990;79-84.
9. J.M. Cavaillon, Possibilities and problems of cytokine measurements, in: H. Redl, G. Schlag (Eds.), Cytokines in Severe Sepsis and Septic Shock, Birkhäuser Verlag, Basel, 1999, pp. 95-119.
10. Cavaillon J.M., Munoz C., Fitting C., Misset B., Carlet J. Circulating cytokines: the tip of the iceberg? Circ. Shock. 38:1992;145-152.
11. Chofflon M., Fellay B. Monitoring multiple sclerosis course and activity with TNF-alpha. Mult. Scler. 4:1998;188-192.
12. Chofflon M., Juillard C., Juillard P., Gauthier G., Grau G.E. Tumor necrosis factor α production as a possible predictor of relapse in patients with multiple sclerosis. Eur. Cytokine Netw. 3:1992;523-531.
13. Claudio L., Martiney J.A., Brosnan C.F. Ultrastructural studies of blood-retina barrier after exposure to interleukin-1β or tumor necrosis factor-α Lab. Invest. 70:1994;850-861.
14. Claudio L., Raine C.S., Brosnan C.F. Evidence of persistent blood-brain barrier abnormalities in chronic-progressive multiple sclerosis. Acta Neuropathol. 90:1995;228-238.
15. Damas P., Ledoux D., Nys M., Vrindts Y., de Groote D., Franchimont P., Lamy M. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann. Surg. 215:1992;356-362.
16. de Winter R.J., Manten A., de Jong Y.P., Adams R., van Deventer S.J.H., Lie K.I. Interleukin 8 released after acute myocardial infarction is mainly bound to erythrocytes. Heart. 78:1997;598-602.
17. Duran I., Martinez-Caceres E.M., Rio J., Barbera N., Marzo M.E., Montalban X. Immunological profile of patients with primary progressive multiple sclerosis. Brain. 122:1999;2297-2307.
18. Endo S., Inada K., Inoue Y., Kuwata Y., Suzuki M., Yamashita H., Hoshi S., Yoshida M. Two types of septic shock classified by the plasma levels of cytokines and endotoxin. Circ. Shock. 38:1992;264-274.
19. Endres S., Cannon J.G., Ghorbani R., Dempsey R.A., Sisson S.D., Lonnemann G., van der Meer J.W.M., Wolff S.M., Dinarello C.A. In vitro production of IL 1β, IL 1α, TNF and IL 2 in healthy subjects: distribution, effects of cyclooxygenase inhibition and evidence of independent gene regulation. Eur. J. Immunol. 19:1989;2327-2333.
20. Engelberts I., Stephens S., Francot G., van der Linden C., Buurman W. Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet. 338:1991;515-516.
21. Fabry Z., Raine C.S., Hart M.N. Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. Immunol. Today. 15:1994;218-224.
22. Franciotta D., Bergamaschi R., Martino G., Zardini E., Desina G., Cosi V. Tumor necrosis factor-α and its soluble receptors in plasma and cerebrospinal fluid of multiple sclerosis patients treated with methylprednisolone. Eur. Cytokine Netw. 10:1999;431-436.
23. Franciotta D., Dondi E., Bergamaschi R., Piccolo G., Melzi d'Eril G.V., Cosi V., Cuccia M. HLA complement gene polymorphisms in multiple sclerosis. J. Neurol. 242:1995;64-68.
24. Franciotta D.M., Grimaldi L.M.E., Martino G.V., Piccolo G., Bergamaschi R., Citterio A., Melzi d'Eril G.V. Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann. Neurol. 26:1989;787-789.
25. Frequin S.T.F.M., Barkhof F., Lamers K.J.B., Hommes O.R., Borm G.F. CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone. Acta Neurol. Scand. 86:1992;291-297.
26. Friedland J.S., Porter J.C., Daryanani S., Bland J.M., Screaton N.J., Versely M.J.J., Griffin G.E., Bennett E.D., Remick D.G. Plasma proinflammatory cytokine concentrations, acute physiology and chronic health evaluation (APACHE) III scores and survival in patients in an intensive care unit. Crit. Care Med. 24:1996;1775-1781.
27. Gay D., Esiri M. Blood-brain barrier damage in acute multiple sclerosis plaques: an immunocytological study. Brain. 114:1991;557-572.
28. Gay F.W., Drye T.J., Dick G.W.A., Esiri M.M. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain. 120:1997;1461-1483.
29. A.S. Hamblin, Cytokines and Cytokine Receptors, Oxford University Press, New York, 1993.
30. Hashim A., Walsh A., Hart C.A., Shenkin A. Cerebrospinal fluid interleukin-6 and its diagnostic values in the investigation of meningitis. Ann. Clin. Biochem. 32:1995;289-296.
31. Hauser S.L., Doolittle T.H., Lincoln R., Brown R.H., Dinarello C.A. Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology. 40:1990;1735-1739.
32. Heinzelmann M., Miller M., Platz A., Gordon L.E., Herzig D.O., Polk H.C. Heparin and enoxaparin enhance endotoxin-induced tumor necrosis factor-α production in human monocytes. Ann. Surg. 229:1999;542-550.
33. Hickey W.F., Hsu B.L., Kimura H.T. T lymphocyte entry into the central nervous system. J. Neurosci. Res. 28:1991;254-260.
34. Jehle A.B., Li Y., Stechschulte A.C., Stechschulte D.J., Dileepan K.N. Endotoxin and mast cell granule proteases synergistically activate human coronary artery endothelial cells to generate interleukin-6 and interleukin-8. J. Interferon Cytokine Res. 20:2000;361-368.
35. Jongen P.J.H., Floris S., Doesburg W.H., Lemmens W.A.J.G., Hommes O.R., Lamers K.J.B. Composite cerebrospinal fluid score in relapsing-remitting and secondary progressive multiple sclerosis. Mult. Scler. 4:1998;108-110.
36. B. Kalman, F.D. Lublin, Cytokine therapy, in: J. Zhang, D. Hafler, R. Hohlfeld, A. Miller (Eds.), Immunotherapy in Neuroimmunologic Diseases, Martin Dunitz Ltd., London, 1998, pp. 261-278.
37. T.O. Kleine (Ed.), Neue Labormethoden für die Liquordiagnostik, Thieme, Stuttgart, 1980.
38. T.O. Kleine, Nervensystem, in: H. Greiling, A.M. Gressner (Eds.), Lehrbuch der Klinischen Chemie und Pathobiochemie, Schattauer, Stuttgart, 1989, pp. 860-893.
39. T.O. Kleine, Blood-brain barrier (BBB) markers, in: E. Melo (Ed.), XX World Congress of Pathology and Laboratory Medicine, Sao Paulo 1999, Monduzzi Editore, Bologna, 1999, pp. 89-94.
40. Kleine T.O. Heterogeneous humoral immune responses in cerebrospinal fluid arising from inflammatory diseases of the central nervous system. Detection of oligoclonal immunoglobulin bands after isoelectric focusing. Anal. Chim. Acta. 393:1999;83-93.
41. Kouwenhoven M., Teleshova N., Özenci V., Press R., Link H. Monocytes in multiple sclerosis: phenotype and cytokine profile. J. Immunol. 112:2001;197-205.
42. Kunihara T., Sasaki S., Shiiya N., Miyatake T., Mafune N., Yasuda K. Proinflammatory cytokines in cerebrospinal fluid in repair of thoracoabdominal aorta. Ann. Thorac. Surg. 71:2001;801-806.
43. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
44. Lassmann H. Neuropathology in multiple sclerosis: new concepts. Mult. Scler. 4:1998;93-98.
45. Lassmann H., Raine C.S., Antel J., Prineas J.W. Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J. Neuroimmunol. 86:1998;213-217.
46. Lassmann H., Suchanek G., Ozawa K. Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis. Ann. Neurol. 36:1994;S42-S46.
47. Lin K.J., Lin J., Hanasawa K., Tani T., Kodama M. Interleukin-8 as a predictor of the severity of bacteremia and infectious disease. Shock. 14:2000;95-100.
48. Lolli F., Halawa I., Link H. Intrathecal synthesis of IgG, IgA, IgM and IgD in untreated multiple sclerosis and controls. Acta Neurol. Scand. 80:1989;238-247.
49. Lopez-Cortes L.F., Marquez-Arbizu R., Jimenez-Jimenez L.M., Jimenez-Mejias E., Caballero-Granado F.J., Rey-Romero C., Polaina M., Pachon J. Cerebrospinal fluid tumor necrosis factor-α, interleukin-1β, interleukin-6, and interleukin-8 as diagnostic markers of cerebrospinal fluid infection in neurosurgical patients. Crit. Care Med. 28:2000;215-219.
50. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 46:1996;907-911.
51. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47:2000;707-717.
52. Lucchinetti C.F., Brück W., Rodriguez M., Lassmann H. Distinct patterns of multiple sclerosis pathology indicate heterogeneity of pathogenesis. Brain Pathol. 6:1996;259-274.
53. Martino G., Consiglio A., Franciotta D.M., Corti A., Filippi M., Vandenbroeck K., Sciacca F.L., Comi G., Grimaldi L.M.E. Tumor necrosis factor α and its receptors in relapsing-remitting multiple sclerosis. J. Neurol. Sci. 152:1997;51-61.
54. Martino G., Hartung H.P. Immunopathogenesis of multiple sclerosis: the role of T cells. Curr. Opin. Neurol. 12:1999;309-321.
55. May L.T., Ghrayeb J., Santhanam U., Tatter S.B., Sthoeger Z., Helfgott D.C., Chiorazzi N., Grieninger G., Sehgal P.B. Synthesis and secretion of multiple forms of beta 2-interferon/B-cell differentiation factor 2/hepatocyte-stimulating factor by human fibroblasts and monocytes. J. Biol. Chem. 263:1988;7760-7766.
56. McDonnell G.V., Hawkins S.A. Primary progressive multiple sclerosis: a distinct syndrome? Mult. Scler. 2:1996;137-141.
57. McLean B.N., Zeman A.Z.J., Barnes D., Thompson E.J. Patterns of blood-brain barrier impairment and clinical features in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 56:1993;356-360.
58. H. Meyer-Rienecker, Heterogenität der multiplen Sklerose: pathogenetische und klinische aspekte, in: W. Firnhaber, K. Dworschak, K. Lauer, M. Nichtweiá (Eds.), Verhandlungen der Deutschen Gesellschaft für Neurologie, Springer, Berlin, Heidelberg, 1991, pp. 48-52.
59. Moller B., Mogensen S.C., Wendelboe P., Bendtzen K., Petersen C.M. Bioactive and inactive forms of tumor necrosis factor-α in spinal fluid from patients with meningitis. J. Infect. Dis. 163:1991;886-889.
60. Nakashima I., Fujihara K., Misu T., Okita N., Takase S., Itoyama Y. Significant correlation between IL-10 levels and IgG indices in the cerebrospinal fluid of patients with multiple sclerosis. J. Neuroimmunol. 111:2000;64-67.
61. Neilson D., Kavanagh J.P., Rao P.N. Kinetics of circulating TNF-α and TNF soluble receptors following surgery in a clinical model of sepsis. Cytokine. 8:1996;938-943.
62. Paemen L., Olsson T., Söderström M., Van Damme J., Opdenakker G. Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur. J. Neurol. 1:1994;55-63.
63. Polman C.H., de Groot C.J.A., Koetsier J.C., Siminia T., Veerman A.J.P. Cerebrospinal fluid cells in multiple sclerosis and other neurological diseases: an immunocytochemical study. J. Neurol. 234:1987;19-22.
64. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtelotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
65. Reder A.T., Genc K., Byskosh P.V., Porrini A.M. Monocyte activation in multiple sclerosis. Mult. Scler. 4:1998;162-168.
66. H. Redl, G. Schlag, S. Bahrami, J. Davies, A. Waage, M. Ceska, W.A. Buurmann, G. Adolf, The cytokine network in trauma and sepsis: TNF and IL-8, in: G. Schlag, H. Redl (Eds.), Pathophysiology of Shock, Sepsis, and Organ Failure, Springer-Verlag, Berlin, Heidelberg, 1993, pp. 468-490.
67. Revesz T., Kidd D., Thompson A.J., Barnard R.O., McDonald W.I. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain. 117:1994;759-765.
68. Rutherford M.S., Witsell A., Schoock L.B. Mechanisms generating functionally heterogeneous macrophages: chaos revisited. J. Leukoc. Biol. 53:1993;602-618.
69. Schindler R., Mancilla J., Endres S., Ghorbani R., Clark S.C., Dinarello C.A. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood. 75:1990;40-47.
70. Schluep M., van Melle G., Henry H., Städler C., Roth-Wicky B., Magistretti P.J. Assessing multiple sclerosis activity: is the in vitro production of tumor necrosis factor-α, interleukins 2, 6, 4, and 10, and immunoglobulin G of value? J. Neurol. 246:1999;1041-1050.
71. Sellebjerg F., Jensen J., Ryder L.P. Costimulatory CD80 (B7-1) and CD86 (B7-2) on cerebrospinal fluid cells in multiple sclerosis. J. Neuroimmunol. 84:1998;179-187.
72. Selmaj K.W. Tumor necrosis factor and anti-tumor necrosis factor approach to inflammatory demyelinating diseases of the central nervous system. Ann. Rheum. Dis. 59(Suppl. I):2000;i94-i102.
73. Sharief M.K., Noori M.A., Ciardi M., Cirelli A., Thompson E.J. Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-α and blood-brain barrier damage. J. Neuroimmunol. 43:1993;15-22.
74. Sharief M.K., Thompson E.J. In vivo relationship of tumor necrosis factor-alpha to blood-brain barrier damage in patients with active multiple sclerosis. J. Neuroimmunol. 38:1992;27-34.
75. Sharif S.F., Hariri R.J., Chang V.A., Barie P.S., Wang R.S., Ghajar J.B.G. Human astrocyte production of tumor necrosis factor-α, interleukin-1β, and interleukin-6 following exposure to lipopolysaccharide endotoxin. Neurol. Res. 15:1993;109-122.
76. Sorensen T.L., Ransohoff R.M. Etiology and pathogenesis of multiple sclerosis. Semin. Neurol. 18:1998;287-294.
77. Spinas G.A., Bloesch D., Keller U., Zimmerli W., Cammisuli S. Pretreatment with ibuprofen augments circulating tumor necrosis factor-α, interleukin-6, and elastase during acute endotoxinemia. J. Infect. Dis. 163:1991;89-95.
78. Sriram S., Rodriguez M. Indictment of the microglia as the villain in multiple sclerosis. Neurology. 48:1997;464-470.
79. Trotter J.L., Collins K.G., van der Veen R.C. Serum cytokine levels in chronic progressive multiple sclerosis: interleukin-2 levels parallel tumor necrosis factor-α levels. J. Neuroimmunol. 33:1991;29-36.
80. Tsukada N., Miyagi K., Matsuda M., Yanagisawa N., Yone K. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J. Neurol. Sci. 102:1991;230-234.
81. Ulvestad E., Williams K., Matre R., Nyland H., Oliver A., Antel J. Fc receptors for IgG on cultured human microglia mediate cytotoxicity and phagocytosis of antibody-coated targets. J. Neuropathol. Exp. Neurol. 53:1994;27-36.
82. van Oosten B.W., Barkhof F., Scholten P.E.T., von Blomberg B.M.E., Ader H.J., Polman C.H. Increased production of tumor necrosis factor α, and not of interferon γ, preceding disease activity in patients with multiple sclerosis. Arch. Neurol. 55:1998;793-798.
83. von Asmuth E.J., Dentener M.A., Bazil V., Bouma M.G., Leeuwenberg J.F., Buurman W.A. Anti-CD-14 antibodies reduce response of cultured human endothelial cells to endotoxin. Immunology. 80:1993;78-83.
84. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J. Exp. Med. 169:1989;333-338.
85. Walker R.W.H., Thompson E.J., McDonald W.I. Cerebrospinal fluid in multiple sclerosis: relationships between immunoglobulins, leukocytes and clinical features. J. Neurol. 232:1985;250-259.
86. Williams K.C., Ulvestad E., Hickey W.F. Immunology of multiple sclerosis. Clin. Neurosci. 2:1994;229-245.
87. Woodroofe M.N. Cytokine production in the central nervous system. Neurology. 45:1995;S6-S10.
88. Woodroofe M.N., Bellamy A.S., Feldmann M., Davison A.N., Cuzner M.L. Immunocytochemical characterization of the immune reaction in the central nervous system in multiple sclerosis. Possible role of microglia in lesion growth. J. Neurol. Sci. 74:1986;135-152.
89. Wucherpfennig K.W., Strominger J.L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell. 80:1995;695-705.
90. P. Zabel, S. Bahrami, Interfering with the production of cytokines in sepsis, in: H. Redl, G. Schlag (Eds.), Cytokines in Severe Sepsis and Septic Shock, Birkhäuser Verlag, Basel, 1999, pp. 261-284.
91. Zeman D., Adam P., Kalistova H., Sobek O., Andel J., Andel M. Cerebrospinal fluid cytologic findings in multiple sclerosis. Acta Cytol. 45:2001;51-59.
92. P. Zöfel (Ed.), Statistik Verstehen. Ein Begleitbuch zur Computergestützten Anwendung, Addison-Wesley, München, Boston, 2001.